Dermal Filler - Medical Devices Pipeline Assessment, 2017

Published : Jun-2017

No. of Pages : 128

order by fax Inquire before Buying request discount

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Dermal Filler Overview 9
3 Products under Development 10
3.1 Dermal Filler - Pipeline Products by Stage of Development 10
3.2 Dermal Filler - Pipeline Products by Territory 11
3.3 Dermal Filler - Pipeline Products by Regulatory Path 12
3.4 Dermal Filler - Pipeline Products by Estimated Approval Date 13
3.5 Dermal Filler - Ongoing Clinical Trials 14
4 Dermal Filler - Pipeline Products under Development by Companies 15
4.1 Dermal Filler Companies - Pipeline Products by Stage of Development 15
4.2 Dermal Filler - Pipeline Products by Stage of Development 17
5 Dermal Filler Companies and Product Overview 19
5.1 Aeon Astron Corporation Company Overview 19
5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 19
5.2 Allergan Inc Company Overview 20
5.2.1 Allergan Inc Pipeline Products & Ongoing Clinical Trials Overview 20
5.3 Almirall Ltd Company Overview 26
5.3.1 Almirall Ltd Pipeline Products & Ongoing Clinical Trials Overview 26
5.4 Anika Therapeutics Inc Company Overview 27
5.4.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 27
5.5 BioPolymer GmbH & Co. KG Company Overview 28
5.5.1 BioPolymer GmbH & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 28
5.6 Bioxis Pharmaceuticals Company Overview 30
5.6.1 Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 30
5.7 Cytophil, Inc. Company Overview 32
5.7.1 Cytophil, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32
5.8 Dermele Skin Care, LLC Company Overview 33
5.8.1 Dermele Skin Care, LLC Pipeline Products & Ongoing Clinical Trials Overview 33
5.9 EternoGen, LLC Company Overview 34
5.9.1 EternoGen, LLC Pipeline Products & Ongoing Clinical Trials Overview 34
5.10 FibroGen Inc Company Overview 35
5.10.1 FibroGen Inc Pipeline Products & Ongoing Clinical Trials Overview 35
5.11 Galderma SA Company Overview 36
5.11.1 Galderma SA Pipeline Products & Ongoing Clinical Trials Overview 36
5.12 Innovia LLC Company Overview 44
5.12.1 Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 44
5.13 Juvenis Ltd. Company Overview 45
5.13.1 Juvenis Ltd. Pipeline Products & Ongoing Clinical Trials Overview 45
5.14 Khorionyx SA Company Overview 46
5.14.1 Khorionyx SA Pipeline Products & Ongoing Clinical Trials Overview 46
5.15 L&C Bio Company Overview 47
5.15.1 L&C Bio Pipeline Products & Ongoing Clinical Trials Overview 47
5.16 Mentor Worldwide LLC Company Overview 48
5.16.1 Mentor Worldwide LLC Pipeline Products & Ongoing Clinical Trials Overview 48
5.17 Moma Therapeutics, Inc. Company Overview 49
5.17.1 Moma Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49
5.18 Mosaic Medical Technologies, Inc Company Overview 50
5.18.1 Mosaic Medical Technologies, Inc Pipeline Products & Ongoing Clinical Trials Overview 50
5.19 Oligo Medic, Inc. Company Overview 51
5.19.1 Oligo Medic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51
5.20 ORGEV Laboratories Company Overview 52
5.20.1 ORGEV Laboratories Pipeline Products & Ongoing Clinical Trials Overview 52
5.21 PetVivo Holdings Inc Company Overview 60
5.21.1 PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 60
5.22 Sekisui Medical Co Ltd Company Overview 62
5.22.1 Sekisui Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 62
5.23 Shanghai Haohai Biological Technology Co Ltd Company Overview 63
5.23.1 Shanghai Haohai Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 63
5.24 Shin Poong PharmCo Ltd Company Overview 65
5.24.1 Shin Poong PharmCo Ltd Pipeline Products & Ongoing Clinical Trials Overview 65
5.25 Sinclair Pharma PLC Company Overview 66
5.25.1 Sinclair Pharma PLC Pipeline Products & Ongoing Clinical Trials Overview 66
5.26 Sofregen Medical Inc Company Overview 77
5.26.1 Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 77
5.27 TEI Biosciences Inc Company Overview 78
5.27.1 TEI Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 78
5.28 University of California Santa Barbara Company Overview 79
5.28.1 University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 79
6 Dermal Filler- Recent Developments 80
6.1 Jun 01, 2017: Suneva Medical Celebrates 10 Years of Steady Growth with Flagship Brand, Bellafill 80
6.2 May 09, 2017: FibroGen Reports First Quarter 2017 Financial Results 80
6.3 May 09, 2017: Oligo Medic Appoints Jerett Creed As CEO 81
6.4 May 05, 2017: Smith & Nephew 2017 First Quarter Trading Report 82
6.5 May 03, 2017: Anika Reports First Quarter 2017 Financial Results 84
6.6 Apr 24, 2017: Juvéderm Vollure XC Dermal Filler -- Long Lasting FDA-Approved Treatment for Diminishing Nasolabial Folds Now Available at Contour Dermatology & Cosmetic Surgery Center 84
6.7 Apr 06, 2017: Galderma Presents Results From Phase 4 Clinical Study of Restylane Refyne at the 15th Aesthetic & Anti-aging Medicine Annual World Congress 85
6.8 Apr 06, 2017: Galderma Presents Results From Phase 4 Clinical Study of Restylane Defyne at the 15th Aesthetic & Anti-aging Medicine Annual World Congress 87
6.9 Apr 04, 2017: Merz Appoints Bob Rhatigan as President and Chief Executive Officer in North America 89
6.10 Mar 21, 2017: Sinclair Pharma Announces Preliminary results for the 12 and 18 months ended 31 December 2016 89
6.11 Mar 20, 2017: JUVEDERM VOLLURE XC Approved By U.S. FDA For Correction Of Facial Wrinkles And Folds In Adults Over The Age Of 21 90
6.12 Mar 01, 2017: FibroGen Reports Fiscal 2016 Financial Results 91
6.13 Feb 15, 2017: Anika Reports Fourth Quarter and Full Year 2016 Financial Results 92
6.14 Feb 15, 2017: Anika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011 93
6.15 Feb 09, 2017: Smith & Nephew Fourth Quarter Trading and Full Year 2016 Results 95
6.16 Feb 09, 2017: Smith & Nephew: Directorate Change 100
6.17 Feb 01, 2017: CROMA-PHARMA opens 12th subsidiary in Germany 100
6.18 Jan 27, 2017: Allergan Launches Juvederm Volite - an Innovative Injectable Treatment Designed to Improve Skin Quality for up to 9 Months 100
6.19 Jan 17, 2017: Sinclair Pharma Announces Pre-Close Trading Update 101
6.20 Jan 12, 2017: Confirmation of CFO leaving Smith & Nephew 102
6.21 Dec 20, 2016: Appointment of Nestle Skin Health CEO ad interim 102
6.22 Dec 12, 2016: Galderma Announces FDA Approval of Restylane Refyne Dermal Filler for Treatment of "Laugh Lines" 103
6.23 Dec 12, 2016: Galderma Announces FDA Approval of Restylane Defyne Dermal Filler for Treatment of "Laugh Lines" 104
6.24 Nov 30, 2016: Graham Baker appointed Chief Financial Officer 105
6.25 Nov 21, 2016: Merz Continues Its Growth in Aesthetics and Neurotoxins 105
6.26 Nov 15, 2016: BTG: Interim results 107
6.27 Nov 08, 2016: FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update 107
6.28 Nov 03, 2016: Smith & Nephew Third Quarter 2016 Trading Report 108
6.29 Oct 26, 2016: Anika Reports Third Quarter 2016 Financial Results 110
6.30 Oct 19, 2016: Facial Aesthetics First in Denver to Offer New Treatment to Help Patients Achieve "Goldilocks Lips" 111
6.31 Oct 18, 2016: JUVEDERM VOLBELLA XC Now Available To Doctors And Patients In The U.S. 111
6.32 Oct 10, 2016: Aesthetics Industry Veteran Pat Altavilla Joins Suneva Medical As Vice President Of Marketing 112
6.33 Oct 06, 2016: BTG: close period update 112
6.34 Sep 27, 2016: Orange County Business Council Study Showcases Economic Impact of Allergan on California Economy 113
6.35 Sep 23, 2016: Biologica Technologies launches Allofill injectable adipose filler at the annual gathering for the American Society of Plastic Surgeons 114
6.36 Sep 21, 2016: Sinclair Pharma: Second Interim Statement (Jan-Jun 2016) 114
6.37 Sep 01, 2016: Sinclair Pharma: Restructuring programme and Board change 116
6.38 Aug 08, 2016: FibroGen Reports Financial Results for the Second Quarter of 2016 116
6.39 Aug 04, 2016: Suneva Appoints Preston Romm To Chief Executive Officer And Fortifies Board Of Directors With Industry Leaders 117
6.40 Jul 28, 2016: Smith & Nephew Second Quarter Trading and First Half 2016 Results 118
6.41 Jul 27, 2016: BTG Announces Appointment of Non-executive Director 121
6.42 Jul 27, 2016: Anika Reports Second Quarter 2016 Financial Results 121
6.43 Jul 18, 2016: Trading update and notification of board changes £17.2m revenue in 1H calendar 2016 122
6.44 Jul 14, 2016: BTG: Annual General Meeting 123
6.45 Jul 11, 2016: CFO to leave Smith & Nephew in early 2017 124
6.46 Jun 16, 2016: Preston Romm Joins Suneva Medical As Chief Operating Officer 124
7 Appendix 125
7.1 Methodology 125
7.2 About GlobalData 128
7.3 Contact Us 128
7.4 Disclaimer 128

1.1 List of Tables
Table 1: Dermal Filler - Pipeline Products by Stage of Development 10
Table 2: Dermal Filler - Pipeline Products by Territory 11
Table 3: Dermal Filler - Pipeline Products by Regulatory Path 12
Table 4: Dermal Filler - Pipeline Products by Estimated Approval Date 13
Table 5: Dermal Filler - Ongoing Clinical Trials 14
Table 6: Dermal Filler Companies - Pipeline Products by Stage of Development 15
Table 7: Dermal Filler - Pipeline Products by Stage of Development 17
Table 8: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 19
Table 9: BioDermal Filler - Product Status 19
Table 10: BioDermal Filler - Product Description 19
Table 11: Allergan Inc Pipeline Products & Ongoing Clinical Trials Overview 20
Table 12: JUVEDERM Volbella - Product Status 20
Table 13: JUVEDERM Volbella - Product Description 20
Table 14: Juvederm Vollure XC - Product Status 21
Table 15: Juvederm Vollure XC - Product Description 21
Table 16: Juvederm VOLUMA XC - Product Status 21
Table 17: Juvederm VOLUMA XC - Product Description 22
Table 18: Allergan Inc - Ongoing Clinical Trials Overview 23
Table 19: Juvederm VOLUMA XC - A Multicenter, Single-blind, Randomized, Parallel-group, Controlled Study of the Safety and Effectiveness of Juvederm VOLUMA XC Injectable Gel for Correction of Temple Hollowing 24
Table 20: Juvederm VOLUMA XC - Clinical Study of Neuramis Volume Lidocaine to Evaluate the Efficacy and Safety for Temporary Restoring the Mid-face Volume 24
Table 21: Juvederm VOLUMA XC - Juvederm Voluma XC for the Treatment of Hypoplastic Chin 24
Table 22: Juvederm Vollure XC - A Safety and Efficacy Study of JUVEDERM VOLIFT with Lidocaine and Restylane for Nasolabial Folds in Chinese Adults 25
Table 23: Juvederm Vollure XC - Prospective Open Label Study to Evaluate the Effectiveness of Juvederm VOLIFT with Lidocaine for Treatment of Dynamic Radial Cheek Line Skin Depressions: BEAM 25
Table 24: Almirall Ltd Pipeline Products & Ongoing Clinical Trials Overview 26
Table 25: Hyaluronic Acid Facial Filler - Product Status 26
Table 26: Hyaluronic Acid Facial Filler - Product Description 26
Table 27: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 27
Table 28: Next Generation ELEVESS Dermal Filler - Product Status 27
Table 29: Next Generation ELEVESS Dermal Filler - Product Description 27
Table 30: BioPolymer GmbH & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 28
Table 31: Matridex - Product Status 28
Table 32: Matridex - Product Description 28
Table 33: Matridur - Product Status 29
Table 34: Matridur - Product Description 29
Table 35: Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 30
Table 36: Cytosial - Product Status 30
Table 37: Cytosial - Product Description 30
Table 38: Cytosmile - Product Status 31
Table 39: Cytosmile - Product Description 31
Table 40: Cytophil, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32
Table 41: Renu Soft Tissue Volumizing Filler - Aesthetic - Product Status 32
Table 42: Renu Soft Tissue Volumizing Filler - Aesthetic - Product Description 32
Table 43: Dermele Skin Care, LLC Pipeline Products & Ongoing Clinical Trials Overview 33
Table 44: Gold Nanoparticle Dermal Filler - Product Status 33
Table 45: Gold Nanoparticle Dermal Filler - Product Description 33
Table 46: EternoGen, LLC Pipeline Products & Ongoing Clinical Trials Overview 34
Table 47: Collagen Scaffold - Aesthetic Procedures - Product Status 34
Table 48: Collagen Scaffold - Aesthetic Procedures - Product Description 34
Table 49: FibroGen Inc Pipeline Products & Ongoing Clinical Trials Overview 35
Table 50: FG-5030 - Product Status 35
Table 51: FG-5030 - Product Description 35
Table 52: Galderma SA Pipeline Products & Ongoing Clinical Trials Overview 36
Table 53: Restylane Lidocaine - Product Status 36
Table 54: Restylane Lidocaine - Product Description 36
Table 55: Restylane Lyft - Hand Rejuvenation - Product Status 37
Table 56: Restylane Lyft - Hand Rejuvenation - Product Description 37
Table 57: Restylane Perlane - Product Status 37
Table 58: Restylane Perlane - Product Description 38
Table 59: Restylane Skinboosters Vital - Product Status 38
Table 60: Restylane Skinboosters Vital - Product Description 38
Table 61: Galderma SA - Ongoing Clinical Trials Overview 39
Table 62: Restylane Perlane - A Randomized, Multi-center, Evaluator-blinded, No-treatment Controlled Study to Evaluate the Efficacy and Safety of Restylane Perlane Lidocaine for Correction of Midface Volume Deficit And/Or Midface Contour Deficiency 40
Table 63: Restylane Perlane - A Randomized, Multi-center, Subject and Evaluator-blinded Study Comparing the Pain and the Safety Profile Associate with Correction of Moderate to Severe Nasolabial Folds Using Restylane Perlane Lidocaine Compared to Restylane Perlane 40
Table 64: Restylane Perlane - An Open, Evaluator-blinded, Non-comparative, Multi-center Study to Assess the Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population 40
Table 65: Restylane Lidocaine - A Multicenter, Active-controlled, Randomized, Evaluator and Subject Blinded, Split-face, Comparative, Non-inferiority and Confirmatory Clinical Study of the Efficacy and Safety Between YYD701-2 and Restylane Perlane Lidocaine for Temporary Correction of Moderate to Severe Nasolabial Folds 41
Table 66: Restylane Lidocaine - A Randomized, Evaluator-blind Comparative Study to Evaluate Performance and Safety of Restylane Lidocaine and No-treatment Control for Treatment of Depressed Facial Acne Scars 41
Table 67: Restylane Lidocaine - A Randomized, Multi-center, Subject and Evaluator-blinded Study Comparing Pain and Safety Profile Associated with Correction of Moderate to Severe Nasolabial Folds Using Restylane with and without Addition of 0.3% Lidocaine Hydrochloride 41
Table 68: Restylane Lidocaine - A Randomized, Multi-center, Subject and Evaluator-blinded Study Comparing the Pain and the Safety Profile Associate with Correction of Moderate to Severe Nasolabial Folds Using Restylane Perlane Lidocaine Compared to Restylane Perlane 42
Table 69: Restylane Lidocaine - An Open, Evaluator-blinded, Non-comparative, Multi-center Study to Assess the Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population 42
Table 70: Restylane Skinboosters Vital - A Randomized, Multi-center, Evaluator-blinded, Split-hand, no Treatment-controlled Study to Evaluate the Safety and Efficacy of Restylane Vital for Skin Rejuvenation of the Dorsal Hands in Chinese Subjects 43
Table 71: Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 44
Table 72: Wrinkle Filler - Product Status 44
Table 73: Wrinkle Filler - Product Description 44
Table 74: Juvenis Ltd. Pipeline Products & Ongoing Clinical Trials Overview 45
Table 75: Tenergel - Product Status 45
Table 76: Tenergel - Product Description 45
Table 77: Khorionyx SA Pipeline Products & Ongoing Clinical Trials Overview 46
Table 78: Autologous Globin Dermal Filler - Product Status 46
Table 79: Autologous Globin Dermal Filler - Product Description 46
Table 80: L&C Bio Pipeline Products & Ongoing Clinical Trials Overview 47
Table 81: Micronized Acellular Dermal Filler - Product Status 47
Table 82: Micronized Acellular Dermal Filler - Product Description 47
Table 83: Mentor Worldwide LLC Pipeline Products & Ongoing Clinical Trials Overview 48
Table 84: Prevelle Shape - Product Status 48
Table 85: Prevelle Shape - Product Description 48
Table 86: Moma Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49
Table 87: Restogel-131 - Product Status 49
Table 88: Restogel-131 - Product Description 49
Table 89: Mosaic Medical Technologies, Inc Pipeline Products & Ongoing Clinical Trials Overview 50
Table 90: Dermal Filler - Product Status 50
Table 91: Dermal Filler - Product Description 50
Table 92: Oligo Medic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51
Table 93: AntaRep - Product Status 51
Table 94: AntaRep - Product Description 51
Table 95: ORGEV Laboratories Pipeline Products & Ongoing Clinical Trials Overview 52
Table 96: Macdermol 18 - Product Status 52
Table 97: Macdermol 18 - Product Description 53
Table 98: Macdermol 21 - Product Status 53
Table 99: Macdermol 21 - Product Description 53
Table 100: Macdermol 24 - Product Status 54
Table 101: Macdermol 24 - Product Description 54
Table 102: Macdermol 30 - Product Status 54
Table 103: Macdermol 30 - Product Description 55
Table 104: Macdermol Bio Lift - Product Status 55
Table 105: Macdermol Bio Lift - Product Description 55
Table 106: Macdermol Bio Revitalization - Product Status 56
Table 107: Macdermol Bio Revitalization - Product Description 56
Table 108: Macdermol Hydro - Product Status 56
Table 109: Macdermol Hydro - Product Description 57
Table 110: Macdermol Lips - Product Status 57
Table 111: Macdermol Lips - Product Description 57
Table 112: MacDermol R - Product Status 58
Table 113: MacDermol R - Product Description 58
Table 114: MacDermol S - Product Status 58
Table 115: MacDermol S - Product Description 59
Table 116: Macdermol Volume - Product Status 59
Table 117: Macdermol Volume - Product Description 59
Table 118: PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 60
Table 119: Dermal Filler - Product Status 60
Table 120: Dermal Filler - Product Description 60
Table 121: Dermal Filler - Lip - Product Status 61
Table 122: Dermal Filler - Lip - Product Description 61
Table 123: Sekisui Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 62
Table 124: NADGL - Product Status 62
Table 125: NADGL - Product Description 62
Table 126: Shanghai Haohai Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 63
Table 127: QST Gel - Product Status 63
Table 128: QST Gel - Product Description 63
Table 129: Third Generation Matrifill - Product Status 64
Table 130: Third Generation Matrifill - Product Description 64
Table 131: Shin Poong PharmCo Ltd Pipeline Products & Ongoing Clinical Trials Overview 65
Table 132: Dermal Filler - Product Status 65
Table 133: Dermal Filler - Product Description 65
Table 134: Sinclair Pharma PLC Pipeline Products & Ongoing Clinical Trials Overview 66
Table 135: Atlean - Product Status 67
Table 136: Atlean - Product Description 67
Table 137: Ellanse Hands-M - Product Status 68
Table 138: Ellanse Hands-M - Product Description 68
Table 139: Ellanse Hands-S - Product Status 69
Table 140: Ellanse Hands-S - Product Description 69
Table 141: Ellansé Lidocaine - Product Status 70
Table 142: Ellansé Lidocaine - Product Description 70
Table 143: Ellansé-E - Product Status 71
Table 144: Ellansé-E - Product Description 71
Table 145: Ellansé-L - Product Status 72
Table 146: Ellansé-L - Product Description 72
Table 147: Ellansé-M - Product Status 73
Table 148: Ellansé-M - Product Description 73
Table 149: Ellansé-S - Product Status 74
Table 150: Ellansé-S - Product Description 74
Table 151: Perfectha G - Product Status 75
Table 152: Perfectha G - Product Description 75
Table 153: Perfectha Lidocaine - Product Status 75
Table 154: Perfectha Lidocaine - Product Description 76
Table 155: Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 77
Table 156: Silk Protein - Tissue/Dermal Filler - Product Status 77
Table 157: Silk Protein - Tissue/Dermal Filler - Product Description 77
Table 158: TEI Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 78
Table 159: Injectable Dermal Filler - Product Status 78
Table 160: Injectable Dermal Filler - Product Description 78
Table 161: University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 79
Table 162: Needle Free Injector - Product Status 79
Table 163: Needle Free Injector - Product Description 79
Table 164: Glossary 127

1.2 List of Figures
Figure 1: Dermal Filler - Pipeline Products by Stage of Development 10
Figure 2: Dermal Filler - Pipeline Products by Territory 11
Figure 3: Dermal Filler - Pipeline Products by Regulatory Path 12
Figure 4: Dermal Filler - Pipeline Products by Estimated Approval Date 13
Figure 5: Dermal Filler - Ongoing Clinical Trials 14

Filed in: Medical Device

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Wound Care Market by Product (Dressings (Foam, Film, Hydrocolloid, Collagen), Devices (NPWT, Assessment, Debridement), Graft, Matrix, Suture, Stapler), Wound(DFUs, Trauma, Surgical, Burn), End User (Hospitals, Clinics) & Region – Global Forecast to 2027 “Increased cases of traumatic injuries and increasing surgical procedures worldwide are driving the overall growth of the wound care market” The global wound care market is projected to reach USD 27.2 billion by 2027 from USD 20.8 billion in 2022, at a CAGR of 5.4% during the forecast period. Market growth is driven by factors such as increase in traumatic injuries, increased in number of surgical wounds and increased spending on traumatic wound management. On the other hand, challenges associated with wound care product validation and shortage of skilled professionals are the major factors hampering the growth of this market. “The advanced wound care products segment accounted for the highest growth rate in the wound care market, by product, during the forecast period” T......	$8150
Rehabilitation Equipment Market by Product (Medical Bed, Mobility Scooter, Walker, Crutcher, Cane, Patient Lift, Sling), Application (Physical, OT, Lower-body Exercise Equipment), End User (Rehabilitation & Physiotherapy Center) – Global Forecast to 2027 “The rehabilitation equipment market is projected to grow at a CAGR of 5.9% between 2022 and 2027.” The global rehabilitation equipment market is projected to reach USD 19.8 billion by 2027 from USD 14.9 billion in 2022, at a CAGR of 5.9% during the forecast period. Increasing geriatric population and obese populations, increasing chronic diseases, high risk of injuries to caregivers during the manual handling of patients, and increasing demand for rehabilitation care, owing to an increasing access to healthcare are the key driving factors in the market. However, a lack of awareness and access to rehabilitation services in emerging countries is a major factor restraining market growth. “Therapy equipment was the largest and fastest-growing segment in the product segment of reha......	$4950
Cold Pain Therapy Market by Product (OTC (Gels, Creams, Patches, Wraps, Pads), Prescription (Motorized, Non-motorized)), Application (Musculoskeletal, Post-Op, Sports Injuries), Distribution Channel (Hospital, Retail, E-Pharmacy) – Global Forecast to 2027 "Increasing sports injuries and active participation are driving the overall growth of the cold pain therapy market." The global cold pain therapy market is projected to reach USD 2.4 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 5.1% during the forecast period. Growth in this market is mainly driven by growing incidence of arthritis and availability of cold pain products at affordable cost. "The OTC products segment accounted for the highest growth rate in the cold pain therapy market, by product, during the forecast period." The cold pain therapy market is segmented into OTC products and prescription products based on product. In 2021, the OTC products segment accounted for the highest growth rate in the cold pain therapy market. Market growth can largely be attri......	$4950
Nerve Repair & Regeneration Market by Products (Neuromodulation Devices (Deep Brain Stimulation, Vagus Nerve Stimulation), Biomaterials (Nerve Conduits, Nerve Wraps), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) – Global Forecast to 2027 “Increasing research investments into the neurological compilations and the expanding geriatric population are pushing the growth of the nerve repair & regeneration market.” The global nerve repair & regeneration market is expected to reach USD 11.6 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 12.1%.The growth in this market is driven by increasing research expenditure on the neurological disorders by the government, the increasing R&D investments by the market players into the neuromodulation and neurostimulation devices and the biomaterials. Also, the expanding geriatric population base dries the growth of the market by placing more demand of the nerve repair and regeneration products. “The biomaterialas segment is anticipated to grow at the fastest ......	$4950
Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) – Global Forecast to 2027 MarketsandMarkets expects particle therapy market is projected to reach USD 1,004 million by 2027 from USD 677 million in 2022, growing at a CAGR of 8.2% from 2022 to 2027. Market growth is driven by factors such as the various advantages offered by the growing global prevalence of cancer, particle therapy advantages over photon therapy, increasing acceptance of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide. However, affordability & accessibility of treatments and infrastructural are expected to limit market growth to a certain extent in the coming years. In this report, the particle therapy market is segmented on the basis of type, product and services, cancer type, application, cancer type, and region. “Treatment Applicat......	$4950
Restorative Dentistry Market by Product (Restorative Material (Glass-ionomers, Bonding Agents, Biomaterial), Implant, Prosthetic, Equipment (Handpiece, Articulator, Furnace), End User (Hospital, Clinic, Laboratory) – Global Forecast to 2027 “The global restorative dentistry market is projected to grow at a CAGR of 6.1%” Restorative dentistry restores mouth functions & its aesthetic state by efficiently managing oral health problems through dental restoration. Dental restoration procedures include the use of implants and prosthetics made by restorative material to restore the function, integrity, and morphology of the missing tooth or to repair the missing parts of the tooth structure resulted from dental caries or injuries. The global restorative dentistry market is projected to reach USD 22.2 billion by 2027 from USD 16.5 billion in 2022, at a CAGR of 6.1%. “The prosthetic materials segment is expected to account for the largest share of the restorative dentistry market” The prosthetic materials segment ......	$4950
Dental Laboratories Market by Material (Metal Ceramic, CAD/CAM Material (Zirconia, Glass Ceramic)), Equipment (Milling Equipment, CAD/CAM System, 3D Printing System, Scanner, Furnace), Prosthetics (Bridge, Crown, Veeners, Denture) – Global Forecast to 2027 “Rapid growth in the geriatric population and the associated increase in the prevalence of edentulism is expected to drive the overall growth of the dental laboratories market.” Edentulism (tooth loss) is a major oral health concern among the elderly; according to the WHO (2020), globally, ~19% of individuals aged between 65 and 74 years are edentulous. Periodontal diseases and dental cavities are the major causes of tooth loss. As the elderly are more susceptible to such ailments, the growth of this population segment will increase the number of people suffering from oral health problems globally. According to the UN, the global geriatric population (aged 65 years and above) will increase from 703 million in 2019 to 1.5 billion in 2050. Thus, significant growth in the geriatric pop......	$4950
Endoscope Reprocessing Market by Product (HLD and Test Strips, Detergents & Wipes, Automated Endoscope Reprocessors (AER), Endoscope Drying, Storage, & Transport Systems, Tracking Solutions), End User (Hospitals, ASCs & Clinics) (2022 – 2027) “Endoscope reprocessing market is projected to grow at CAGR of 9.7% from 2022 to 2027” The global endoscope reprocessing market is projected to USD 3.8 billion by 2027 from USD 2.4 billion in 2022, at a CAGR of 9.7% from 2022 to 2027.The growth of this market is driven owing to increasing requirement for endoscopy to diagnose and treat target diseases, high risk of Endoscope-associated infections due to contaminated endoscopes, Growing geriatric population and leading to increase in endoscopic procedures, and Increasing emphasis on improving reprocessing guidelines by healthcare authorities. Also, Increasing investments, funds, and grants to improve healthcare infrastructure and research areas of endoscopy is anticipated to offer an opportunity for the growth of the market during th......	$4950
Polymethyl Methacrylate (PMMA) Market by Grade (General Purpose, Optical), Form(Extruded Sheet, Cast Acrylic Sheet, Pellets, Beads),End-Use Industry(Signs & Displays, Construction, Automotive, Lighting Fixtures, Electronics, Marine, Healthcare) & Region – Global Forecast to 2027 “Rising demand from the electronics industry and expected recovery from impact of COVID-19 and rising penetration of EVs expected to drive market.” The global Polymethyl Methacrylate (PMMA) market is projected to grow from USD 4.8 Billion in 2022 to USD 6.3 Billion by 2027, at a CAGR of 5.4% during the forecast period. Increasing usage of PMMA in construction, automotive, electronics, and other end-use industries are driving the demand for PMMA during the forecast period. However, availability of low-cost substitutes is expected to hamper market growth. PMMA is a versatile, recyclable, sustainable, and durable material, owing to which it is gaining traction across several industrial applications. Due to its superior properties and the changing government policies such as European Gr......	$4950
Microtome Market by Product (Instruments, (Rotary), Accessories (Microtome Blades), Application (Disease Diagnosis, Medical Research), Technology (Fully Automated, Semi-automated, Manual), End User (Hospital, Clinical Labs) – Global Forecast to 2027 “The hospital laboratories is projected to grow at CAGR of 7.1% from 2022 to 2027” Based on End user the market is classified into, The hospital laboratories, clinical laboratories, and other end users . The growth of this market is majorly driven by the increasing number of specialty diagnostic tests performed in hospital laboratories, rising number of in-house clinical diagnostic procedures in hospitals, rising number of hospitals across the globe, and the growing trend of establishing in-house clinical diagnostic capabilities in hospitals. “Microtome instruments in the product segment to witness the highest shares during the forecast period.” Based on the product, the microtome market is segmented into Microtome Instruments: Rotary Microtomes, Cryostat Microtomes, Vibra......	$4950

Dermal Filler - Medical Devices Pipeline Assessment, 2017

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Wound Care Market by Product (Dressings (Foam, Film, Hydrocolloid, Collagen), Devices (NPWT, Assessment, Debridement), Graft, Matrix, Suture, Stapler), Wound(DFUs, Trauma, Surgical, Burn), End User (Hospitals, Clinics) & Region – Global Forecast to 2027

Rehabilitation Equipment Market by Product (Medical Bed, Mobility Scooter, Walker, Crutcher, Cane, Patient Lift, Sling), Application (Physical, OT, Lower-body Exercise Equipment), End User (Rehabilitation & Physiotherapy Center) – Global Forecast to 2027

Cold Pain Therapy Market by Product (OTC (Gels, Creams, Patches, Wraps, Pads), Prescription (Motorized, Non-motorized)), Application (Musculoskeletal, Post-Op, Sports Injuries), Distribution Channel (Hospital, Retail, E-Pharmacy) – Global Forecast to 2027

Nerve Repair & Regeneration Market by Products (Neuromodulation Devices (Deep Brain Stimulation, Vagus Nerve Stimulation), Biomaterials (Nerve Conduits, Nerve Wraps), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) – Global Forecast to 2027

Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) – Global Forecast to 2027

Restorative Dentistry Market by Product (Restorative Material (Glass-ionomers, Bonding Agents, Biomaterial), Implant, Prosthetic, Equipment (Handpiece, Articulator, Furnace), End User (Hospital, Clinic, Laboratory) – Global Forecast to 2027

Dental Laboratories Market by Material (Metal Ceramic, CAD/CAM Material (Zirconia, Glass Ceramic)), Equipment (Milling Equipment, CAD/CAM System, 3D Printing System, Scanner, Furnace), Prosthetics (Bridge, Crown, Veeners, Denture) – Global Forecast to 2027

Endoscope Reprocessing Market by Product (HLD and Test Strips, Detergents & Wipes, Automated Endoscope Reprocessors (AER), Endoscope Drying, Storage, & Transport Systems, Tracking Solutions), End User (Hospitals, ASCs & Clinics) (2022 – 2027)

Polymethyl Methacrylate (PMMA) Market by Grade (General Purpose, Optical), Form(Extruded Sheet, Cast Acrylic Sheet, Pellets, Beads),End-Use Industry(Signs & Displays, Construction, Automotive, Lighting Fixtures, Electronics, Marine, Healthcare) & Region – Global Forecast to 2027

Microtome Market by Product (Instruments, (Rotary), Accessories (Microtome Blades), Application (Disease Diagnosis, Medical Research), Technology (Fully Automated, Semi-automated, Manual), End User (Hospital, Clinical Labs) – Global Forecast to 2027